NO20006027L - Anvendelse av indigoid-bisindolderivater til fremstilling av et medikament for å hemme cyclinavhengige kinaser - Google Patents

Anvendelse av indigoid-bisindolderivater til fremstilling av et medikament for å hemme cyclinavhengige kinaser

Info

Publication number
NO20006027L
NO20006027L NO20006027A NO20006027A NO20006027L NO 20006027 L NO20006027 L NO 20006027L NO 20006027 A NO20006027 A NO 20006027A NO 20006027 A NO20006027 A NO 20006027A NO 20006027 L NO20006027 L NO 20006027L
Authority
NO
Norway
Prior art keywords
indigoid
medication
preparation
dependent kinases
inhibit cyclin
Prior art date
Application number
NO20006027A
Other languages
English (en)
Other versions
NO20006027D0 (no
Inventor
Gerhard Eisenbrand
Ralph Hoessl
Doris Marko
Weici Tang
Laurent Meijer
Original Assignee
Gerhard Eisenbrand Inst Fuer L
Cnrs Ct Nat De Rech Scient Fra
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP98109845A external-priority patent/EP0966963A1/en
Application filed by Gerhard Eisenbrand Inst Fuer L, Cnrs Ct Nat De Rech Scient Fra filed Critical Gerhard Eisenbrand Inst Fuer L
Publication of NO20006027D0 publication Critical patent/NO20006027D0/no
Publication of NO20006027L publication Critical patent/NO20006027L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20006027A 1998-05-29 2000-11-28 Anvendelse av indigoid-bisindolderivater til fremstilling av et medikament for å hemme cyclinavhengige kinaser NO20006027L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98109845A EP0966963A1 (en) 1998-05-29 1998-05-29 Use of indigoid bisindole derivatives as CDK1 inhibitors
EP99105693 1999-03-19
PCT/EP1999/003625 WO1999062503A2 (en) 1998-05-29 1999-05-26 Use of indigoid bisindole derivatives for the manufacture of a medicament to inhibit cyclin dependent kinases

Publications (2)

Publication Number Publication Date
NO20006027D0 NO20006027D0 (no) 2000-11-28
NO20006027L true NO20006027L (no) 2001-01-22

Family

ID=26149292

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20006027A NO20006027L (no) 1998-05-29 2000-11-28 Anvendelse av indigoid-bisindolderivater til fremstilling av et medikament for å hemme cyclinavhengige kinaser

Country Status (14)

Country Link
EP (1) EP1079826B1 (no)
JP (1) JP2002516851A (no)
KR (1) KR20010078722A (no)
AT (1) ATE233560T1 (no)
AU (1) AU762830B2 (no)
BR (1) BR9910810A (no)
CA (1) CA2333661A1 (no)
DE (1) DE69905712T2 (no)
DK (1) DK1079826T3 (no)
ES (1) ES2194468T3 (no)
HU (1) HUP0102240A3 (no)
IL (1) IL139914A0 (no)
NO (1) NO20006027L (no)
WO (1) WO1999062503A2 (no)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6624171B1 (en) 1999-03-04 2003-09-23 Smithkline Beecham Corporation Substituted aza-oxindole derivatives
GB9904933D0 (en) 1999-03-04 1999-04-28 Glaxo Group Ltd Compounds
WO2000061124A2 (en) * 1999-04-12 2000-10-19 Gerhard Eisenbrand Use off cell membrane penetrating indigoid bisindole derivatives
EA200101046A1 (ru) * 1999-04-12 2002-04-25 Герхард Айзенбранд Производные индигоидных бис-индолов
WO2002030410A2 (en) * 2000-10-10 2002-04-18 Board Of Regents, The University Of Texas System Suppression of cyclin kinase activity for prevention and treatment of infections
DE10053474A1 (de) * 2000-10-24 2002-05-02 Schering Ag Schwefelhaltige Indirubinderivate, deren Herstellung und Verwendung
DE10061162A1 (de) * 2000-11-30 2002-07-11 Schering Ag Aryl-substituierte Indirubinderivate, deren Herstellung und Verwendung
AU2002246659A1 (en) * 2000-12-18 2002-08-06 The Government Of The United States Of America, As Represented By The Secretary, Department Of Healt Benzoylalkylindolepyridinium compounds and pharmaceutical compositions comprising such compounds
FR2821358B1 (fr) * 2001-02-27 2006-04-07 Aventis Pharma Sa Oxindoles inhibiteurs de cdk-1 et leur application en therapeutique
DE10114138C2 (de) * 2001-03-16 2003-03-27 Schering Ag Cdk-inhibitorische Indirubinderivate mit erhöhter Löslichkeit
DE10125763A1 (de) * 2001-05-17 2002-11-28 Schering Ag Verwendung selektiver Indirubinderivate als VEGF-R Inhibitoren
DE10129028A1 (de) * 2001-06-11 2003-01-02 Schering Ag Lösliche Cdk-inhibitorische Indirubinderivate
TW201041580A (en) * 2001-09-27 2010-12-01 Alcon Inc Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucoma
US20050154046A1 (en) 2004-01-12 2005-07-14 Longgui Wang Methods of treating an inflammatory-related disease
US6566341B1 (en) * 2001-12-13 2003-05-20 Natrogen Therapeutics, Inc. Derivative of isoindigo, indigo and indirubin for the treatment of cancer
US7582670B2 (en) 2001-12-13 2009-09-01 Natrogen Therapeutics, Inc. Methods of treating an inflammatory-related disease
US8563525B2 (en) 2004-01-12 2013-10-22 Natrogen Therapeutics International, Inc. Methods of treating an inflammatory-related disease
ATE484514T1 (de) * 2001-12-13 2010-10-15 Natrogen Therapeutics Inc Derivate von isoindigo, indigo und indirubin und deren verwendung bei der behandlung von krebs
BR0308985A (pt) * 2002-04-03 2005-01-04 Allergan Inc (3z)-3-(3-hidro-isobenzofuran-1-ilideno)-1,3-diidro-2h-i ndol-2-onas como inibidores da cinase
CN1199946C (zh) * 2002-10-29 2005-05-04 无锡杰西医药科技有限公司 一种特异性吲哚类化合物及制备方法与其在治疗和预防癌症等疾病中的应用
KR100588803B1 (ko) * 2004-01-27 2006-06-12 학교법인조선대학교 암세포주에 항암활성을 지닌 인디루빈 유도체
BRPI0511057A (pt) * 2004-05-12 2007-11-27 Bayer Cropscience Gmbh regulação de crescimento da planta
MX2007001155A (es) * 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
CN1329376C (zh) * 2005-09-19 2007-08-01 无锡杰西医药科技有限公司 一种n(1)-烃基-3′-肟基靛玉红衍生物(i)的制备方法及其医学应用
JP4587961B2 (ja) * 2006-01-16 2010-11-24 独立行政法人科学技術振興機構 神経因性疼痛治療剤
EP2379549B1 (en) 2008-12-22 2016-09-21 Eisenbrand, Gerhard 7-azaindirubins, 7'-azaindirubins, 7-7'-diazaindirubin and the corresponding 3'-oxime ether derivates: production thereof, their production and use as a medicament
EP2199292A1 (en) 2008-12-22 2010-06-23 Technische Universität Kaiserlautern 7-azaindirubins, 7'-azaindirubins, 7-7'-diazaindirubin and the corresponding 3'-oxime ether derivates: production thereof, their production and use as a medicament
FR2945747A1 (fr) 2009-05-25 2010-11-26 Centre Nat Rech Scient Composition pharmaceutique antitumorale comprenant un inhibiteur de cdks et un inhibiteur de la croissance cellulaire
FR2952818B1 (fr) * 2009-11-23 2013-05-31 Oreal Composition contenant au moins un precurseur de coloration derive d'indole, au moins un colorant indoline dione et au moins un compose organique liquide
KR101180030B1 (ko) 2010-02-05 2012-09-05 광주과학기술원 사이클린-의존적 키나제 저해제로서 항암 활성을 지닌 인디루빈-3'-옥심 유도체
US8524121B2 (en) * 2012-01-27 2013-09-03 Xerox Corporation Bi-indoline-dithione polymers
WO2013142817A2 (en) 2012-03-23 2013-09-26 Dennis Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
CN103333161B (zh) * 2013-05-28 2015-09-30 滁州市洛达生物科技有限公司 1’-氧代靛玉红的制备和用途
CA3217792A1 (en) 2021-05-07 2022-11-10 Kymera Therapeutics, Inc Cdk2 degraders and uses thereof
CN113773243B (zh) * 2021-09-01 2023-01-06 大连理工大学 一种有机催化氧化吲哚自缩合制备异靛蓝类化合物的方法
MX2024004264A (es) 2021-10-08 2024-07-10 Azora Therapeutics Inc Derivados de agonistas de los receptores de aril hidrocarburos.
CN115925610B (zh) * 2022-12-05 2025-04-04 天津中医药大学 6,6'-二异戊烯基靛玉红及其制备方法与应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS617254A (ja) * 1984-06-20 1986-01-13 Isukura Sangyo Kk ビスインドリノンおよびそれを主成分とする制癌剤
EP0929520B1 (en) * 1996-08-23 2005-11-02 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease

Also Published As

Publication number Publication date
BR9910810A (pt) 2001-02-13
KR20010078722A (ko) 2001-08-21
NO20006027D0 (no) 2000-11-28
WO1999062503A3 (en) 2000-01-27
DE69905712D1 (de) 2003-04-10
AU4368799A (en) 1999-12-20
HUP0102240A3 (en) 2003-05-28
EP1079826B1 (en) 2003-03-05
JP2002516851A (ja) 2002-06-11
AU762830B2 (en) 2003-07-03
HUP0102240A2 (hu) 2001-11-28
WO1999062503A2 (en) 1999-12-09
CA2333661A1 (en) 1999-12-09
EP1079826A2 (en) 2001-03-07
DK1079826T3 (da) 2003-06-23
ATE233560T1 (de) 2003-03-15
ES2194468T3 (es) 2003-11-16
IL139914A0 (en) 2002-02-10
DE69905712T2 (de) 2004-01-29

Similar Documents

Publication Publication Date Title
IL139914A0 (en) Use of indigoid bisindole derivatives for the manufacture of a medicament to inhibit cyclin dependent kinases
MXPA03010810A (es) Pirimidinas inhibidoras de cdk, su obtencion y su uso como medicamentos.
FR21C1010I1 (no)
MY137843A (en) Pyrazolopyrimidines as cyclin dependent kinase inhibitors
MY134589A (en) Imidazopyrazines as cyclin dependent kinase inhibitors
UY27592A1 (es) Nuevo uso
WO1999057117A3 (de) Indolderivate und deren verwendung zur behandlung von malignen und anderen, auf pathologischen zellproliferationen beruhenden erkrankungen
BR0108394A (pt) Inibidores de cinase de proteìna de 2-indolinona de pirrol substituìdo
BR0312633A (pt) Composto, uso do composto, composição farmacêutica, processo para a preparação de um composto
WO2002024701A3 (en) Substituted azepino[4,5b)indole derivatives
CA2309551A1 (en) Aminothiazole inhibitors of cyclin dependent kinases
BR0016420A (pt) Aminotiazóis inibidores de cinases dependentes de ciclinas
WO2004026310A8 (en) Novel imidazopyrazines as cyclin dependent kinase inhibitors
AR022665A1 (es) Compuestos farmaceuticamente activos
MY138352A (en) Benzothiazole derivatives
TR200001081T2 (tr) CDKS inhibitörleri olarak ikame edilmiş 4-amino tiyazol-2-il bileşikleri
NO20014728L (no) Derivater av pyrimido[6,1-a]isokinolin-4-on
TR200101860T2 (tr) Sikline bağlı kinaz inhibitörleri olarak 4-alkenil (ve alkinil) oksidoller
MXPA02005844A (es) Inhibidores de cinasas de proteina.
WO2005037825A3 (en) Protein kinase inhibitors
BG104813A (bg) Заместени индолинони с инхибиращ ефект върху кинази и комплекси циклин/cdk
DE69924292D1 (de) Pyrazol verbindungen und ihre verwendung
PL375697A1 (en) Pyrazolopyrimidines as cyclin-dependent kinase inhibitors
PE20030236A1 (es) Derivados de bencimidazol 1-aril-2-n,s- u o-sustituidos, obtencion de medicamentos y preparados farmaceuticos que contienen estos derivados
HUP0000854A2 (hu) 4-[6-Fluor-(1H)-indol-3-il]-1,2,3,6-tetrahidropiridin-származékok, az ezeket tartalmazó gyógyszerkészítmények és eljárás mindezek előállítására

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application